

Preface to the Second Edition *xv*

1	Solid State and Polymorphism of the Drug Substance in the Context of Quality by Design and ICH Guidelines Q8–Q12	1
	<i>Markus von Raumer and Rolf Hilfiker</i>	
1.1	Introduction	1
1.2	A Short Introduction to Polymorphism and Solid-State Development	1
1.3	A Short Introduction to Quality by Design (QbD)	3
1.4	The Solid State in the Context of Pharmaceutical Development	7
1.4.1	Typical Drug Discovery and Development	7
1.4.2	The Solid State at the Interface of Drug Substance and Drug Product	10
1.4.3	Biopharmaceutics and Bioavailability of Solids	11
1.4.4	Pharmaceutical Quality Assessment	14
1.5	Solid-State Development at Various Stages of the Pharmaceutical Development Process	15
1.5.1	The Solid State in the Discovery Phase	16
1.5.2	Salt and Co-crystal Screening and Selection	16
1.5.3	Polymorph Screening, Polymorph Landscape, and Polymorph Transformations	17
1.5.4	Crystallization and Downstream Processes	20
1.5.5	Formulation	21
1.5.6	Analytical Methods for Characterization and Physical Purity Determination	22
1.6	Conclusions	23
	References	23
2	Alternative Solid Forms: Salts	31
	<i>P.H. Stahl, Bertrand Sutter, Arnaud Grandeury, and Michael Mutz</i>	
2.1	Introduction	31
2.2	Salt Formation and Polymorphism in Pharmaceutical Development	31
2.3	Target Properties of Active Substances for Drug Products	33
2.3.1	Injectables	34

2.3.2	Solid Dosage Forms	35
2.3.3	Dosage Forms for Other Routes of Application	36
2.3.3.1	Inhalation	36
2.3.3.2	Topical Products and Transdermal Route	36
2.4	The Basics of Salt Formation	37
2.4.1	Dissociation Constant	37
2.4.2	Ionization and pH	39
2.4.3	Solubility	40
2.4.4	Disproportionation	43
2.5	Approaches to Salt Preparation and Characterization	45
2.5.1	Initial Data	45
2.5.2	Selection of Salt Formers	45
2.5.3	Salt Preparation Procedures	46
2.6	Selection Strategies	49
2.6.1	Points to be Considered	49
2.6.2	Final Decision	51
2.6.3	Salt Form and Life Cycle Management of Drug Products	52
2.7	Case Reports	53
2.7.1	Overview of Salt Forms Selected	53
2.7.2	The Salt Selection Process	53
2.7.3	Case 1: NVP-BS001	53
2.7.4	Case 2: NVP-BS002	54
2.8	Discussion and Decision	56
	References	56

3 Alternative Solid Forms: Co-crystals 61

Johan Wouters, Dario Braga, Fabrizia Grepioni, Luc Aerts, and Luc Quére

3.1	Introduction	61
3.2	Types of Pharmaceutical Co-crystals	62
3.2.1	Salts vs Co-crystals	62
3.2.2	Ionic Co-crystals of API	63
3.2.3	Polymorphism and Co-crystals	65
3.3	Relevant Pharmaceutical Co-crystal Properties	65
3.3.1	Solubility	66
3.3.2	Dissolution Rate	67
3.3.3	Bioavailability	69
3.3.4	Melting Point	69
3.3.5	Stability	70
3.3.6	Challenges and Undesired Effect of Co-crystallization	71
3.4	Analytical Tools to Characterize Co-crystals	73
3.4.1	Microscopy	74
3.4.2	X-Ray Diffraction	75
3.4.3	Thermal Analysis	77
3.4.4	Vibrational Spectroscopy	77
3.4.5	Solid-State NMR	78
3.5	Patent Literature Review	79
3.6	Current View on Regulatory Aspects of PCCs	83

3.6.1	Rules Governing Manufacturing (API GMP)	84
3.6.2	ICH Tripartite Guidelines on Specifications for New Drug Substances and New Drug Products	85
3.7	Conclusions	85
	Acknowledgment	85
	References	86
4	Thermodynamics of Polymorphs and Solvates	91
	<i>Gerard Coquerel</i>	
4.1	Basic Notions	91
4.1.1	Chemical Purity	92
4.1.2	Isotopic Purity	92
4.1.3	Structural Purity	92
4.1.4	Stability of the Component	93
4.1.5	Polymorphism, Desmotropy, Allotropism, and Chirality	93
4.1.6	Gibbs Phase Rule	93
4.1.7	Unary System or Unary Section Without Polymorphism	94
4.2	Unary System or Unary Section with Polymorphism	95
4.2.1	Access to Polymorphs	97
4.2.2	Mechanisms of Polymorphic Transition	98
4.3	Polymorphism in Binary Systems	98
4.3.1	No Mixed Crystals	98
4.3.1.1	Polymorphism of One Component Only	98
4.3.1.2	Three Enantiotropic Polymorphs	100
4.3.1.3	Two Enantiotropic Polymorphs and One Form with Monotropic Character	100
4.3.1.4	One Stable Polymorph and Two Forms with a Monotropic Character	100
4.3.1.5	Polymorphism of a Stoichiometric Compound	100
4.3.2	Polymorphism and Mixed Crystals	102
4.3.2.1	Polymorphism of One Component Only	102
4.3.2.2	Two Stable Polymorphic Forms for One Component with Full Miscibility in the Solid State (at a Certain Temperature)	105
4.3.2.3	Two Stable Polymorphic Forms for One Component with Limited Miscibility in the Solid State	108
4.3.2.4	One Stable Form and One Metastable Form (Monotropic Character) with Full Miscibility for the Metastable Form	109
4.3.2.5	One Stable Form and One Metastable Form (Monotropic Character) with Full Miscibility for the Metastable Form	111
4.3.2.6	Two Isostructural Monotropic Forms When Mixed Could Lead to an Enantiotropy	112
4.3.2.7	Limitations of the Concept of Polymorphism and Other Solid(s) to Solid(s) Transitions	112
4.3.3	Solvates	114
4.3.3.1	Differentiation Between Stoichiometric and Nonstoichiometric Solvates	116
4.3.3.2	Hygroscopicity, Deliquescence, and Efflorescence	117

4.4	Ternary Systems	119
4.4.1	Chiral Discrimination via the Formation of Solvates	121
4.5	Temperature of Desolvation – T_g and New Polymorphs Only Accessible Through a Smooth Solvation – Desolvation Process	123
4.6	Concluding Remarks	126
	Acknowledgments	127
	References	127

5 Toward Computational Polymorph Prediction 133

Sarah L. Price and Louise S. Price

5.1	Could a Computer Predict Polymorphs for the Pharmaceutical Industry?	133
5.1.1	Predicting the Thermodynamically Most Stable Structure from the Chemical Diagram	134
5.1.2	Using Crystal Structure Prediction Studies as a Complement to Solid-form Screening	134
5.2	Methods of Calculating the Relative Energies of Crystals	136
5.2.1	Lattice Energy	136
5.2.2	Free Energy	139
5.3	Searching for Possible Crystal Structures	140
5.4	Comparing Crystal Structures	141
5.5	Calculation of Properties from Crystal Structures	142
5.5.1	Spectroscopic – PXRD, IR, ss-NMR	142
5.5.2	Other Properties: Solubilities, Morphologies, and Mechanical Properties	143
5.6	Crystal Energy Landscapes	145
5.6.1	Interpretation of Crystal Energy Landscapes	145
5.6.2	Example of Tazofelone	146
5.7	Potential Uses of Crystal Energy Landscapes in the Pharmaceutical Industry	148
5.7.1	Confirming the Most Stable Structure is Known	148
5.7.2	Suggesting Experiments to Find New Polymorphs	148
5.7.3	Aiding Structural Characterization from Limited Experimental Data	149
5.7.4	Anticipating Disorder	149
5.7.5	Understanding Crystallization Behaviors	149
5.8	Outlook	150
	References	151

6 Hygroscopicity and Hydrates in Pharmaceutical Solids 159

Susan M. Reutzel-Edens, Doris E. Braun, and Ann W. Newman

6.1	Introduction	159
6.2	Thermodynamics of Water–Solid Interactions	160
6.3	Hygroscopicity	161
6.3.1	Moisture Sorption Analysis	162
6.3.2	Hygroscopic Behaviors in Pharmaceutical Solids	166
6.4	Hydrates	168

6.4.1	Statistics of Hydrate Appearance	168
6.4.2	Hydrate Crystallization	170
6.4.3	Structures and Properties	174
6.5	Significance and Strategies for Developing Hydrate-Forming Systems	180
6.6	Conclusions	184
	References	184
7	The Amorphous State	189
	<i>Marc Descamps, Emeline Dudognon, and Jean-François Willart</i>	
7.1	Introduction	189
7.2	Amorphous/Crystalline Solids: Terminology and Brief Confrontation	190
7.2.1	Structural Aspects	190
7.2.2	The Concept(s) of Solid State: Rheological Aspect	191
7.2.3	Crystal Melting vs Glass Softening	192
7.3	Order and Disorder: Structural Identification of Amorphous and Crystal States	193
7.3.1	How Disordered can a Crystal Be?	193
7.3.1.1	Crystallinity: Definition, Experimental Identification	193
7.3.1.2	Small or Disordered "Perfect" Crystals	193
7.3.2	Structure of Glassy and Amorphous Compounds. How Ordered can They be?	194
7.4	Amorphous Stability, Crystallization Avoidance, and Glass Formation	198
7.4.1	Metastability, Driving Force for Crystallization	198
7.4.2	Kinetics of Crystallization via Nucleation and Growth	198
7.4.3	Conventional Glass Formation	201
7.4.4	Notes on the Assessment and Prediction of Amorphous Stability	202
7.4.4.1	Role of Molecular Mobility	202
7.4.4.2	Role of the Liquid/Crystal Interface Energy and Structural Similarity	202
7.4.4.3	Role of Polymorphism	203
7.4.4.4	Heterogeneous Nucleation	204
7.4.4.5	Confinement and Size Effect	204
7.4.4.6	To Summarize	205
7.5	The Glass Transition	205
7.5.1	Calorimetric Signature at T_g	205
7.5.2	Calorimetric Glass Transition: Signification	206
7.5.3	The C_p Jump at T_g : <i>Fragile</i> and <i>Strong</i> Glass Formers	207
7.5.4	Glass Transition and Entropy Crisis: The Kauzmann Paradox	207
7.5.5	Glassy Amorphous State: Instability and Energy Landscape	208
7.6	Molecular Mobility for $T > T_g$	210
7.6.1	Mobility of Fragile and Strong Glass Formers	210
7.6.2	Link Between Mobility and Entropy	212
7.6.3	Cooperative Rearrangement Regions (CRR)	213

7.6.4	Dynamic Heterogeneity: Non-exponentiality of the Relaxation	213
7.7	Molecular Mobility and Instability for $T < T_g$	214
7.7.1	The Aging Phenomenon	214
7.7.2	Approximate Assessment of Stability	215
7.7.2.1	Fictive Temperature	216
7.7.3	Nonlinearity	217
7.7.4	Secondary Relaxations	218
7.8	Multicomponent Amorphous Systems: Solubility and Stability Issues	220
7.8.1	Solubility: Comparison of Crystalline and Amorphous States	220
7.8.2	T_g of Amorphous Multicomponent System	223
7.8.3	Improved Dissolution Properties	224
7.8.4	Mixing and Stabilization	224
7.9	Methods of Amorphization	226
7.10	Influence of Processing on Properties	230
7.11	Concluding Remarks	231
	References	232
8	Approaches to Solid-Form Screening	241
	<i>Rolf Hilfiker, Fritz Blatter, Martin Szelagiewicz, and Markus von Raumer</i>	
8.1	Screening for Salts and Co-crystals	242
8.1.1	Example of a Co-crystal Screen	243
8.2	Polymorphs, Hydrates, and Solvates	245
8.3	Screening for Polymorphs, Hydrates, and Solvates	245
8.3.1	Crystallization Methods	248
8.3.2	Choice of Solvent	250
8.3.3	Types of Polymorph Screens	251
8.3.4	Characterization and Selection	253
8.4	Conclusion	255
	References	256
9	Nucleation	261
	<i>Marco Mazzotti, Thomas Vetter, David R. Ochsenein, Giovanni M. Maggioni, and Christian Lindenberg</i>	
9.1	Introduction	261
9.2	Homogeneous Nucleation	262
9.2.1	Classical Nucleation Theory	264
9.2.2	Two-Step Nucleation Theory	266
9.3	Heterogeneous and Secondary Nucleation	268
9.3.1	Heterogeneous Nucleation	268
9.3.2	Secondary Nucleation	268
9.4	Characterization of Nucleation	270
9.4.1	Deterministic Nucleation Rates	270
9.4.2	Stochastic Nucleation Rates	272
9.5	Order of Polymorph Appearance – Ostwald's Rule of Stages	275
9.6	To Seed or Not to Seed?	277
9.6.1	Process Control	277

9.6.2	Polymorphism Control	279
9.6.3	Impurity Control	279
	References	280
10	Crystallization Process Modeling	285
	<i>Marco Mazzotti, Thomas Vetter, and David R. Ochsenbein</i>	
10.1	Introduction	285
10.1.1	Population Balance Equations	286
10.1.2	Notes Regarding Population Balance Models	288
10.1.2.1	Energy Balances and Fluid Dynamics	288
10.1.2.2	Solution of Population Balance Equations	288
10.1.2.3	Applications	289
10.2	System Characterization and Optimization	289
10.2.1	Crystal Growth	290
10.2.2	Polymorph Transformation	291
10.2.3	Agglomeration	292
10.2.4	Optimization	295
10.3	Multidimensional Population Balance Modeling	297
10.4	Conclusion	300
	References	301
11	Crystallization Process Scale-Up, a Quality by Design (QbD) Perspective	305
	<i>Andrei A. Zlota</i>	
11.1	Introduction	305
11.2	API Critical Quality Attributes (CQAs)	306
11.3	Statistical Design of Experiments (DoE) for Crystallization Process Development	306
11.3.1	Example: DoE Methodology to Develop a Robust Crystallization Process, a Case of an API Developed as a Polymorphic Mixture	307
11.4	Process Analytical Technology (PAT) for Polymorph Control	314
11.5	Mixing and Scale-Up Investigations	316
11.5.1	Scale-Up Factors, Mass Transfer	316
11.5.2	Scale-Up Factors in Crystallization Processes	318
11.5.3	Mixing Impact on the Metastable Zone Width (MSZW)	324
11.5.4	Disappearing Polymorphs During Scale-Up	324
11.5.5	Polymorph Control Methods Based on Mixing	324
11.5.6	Heat Transfer	325
11.6	Conclusions and Outlook	326
	References	326
12	Processing-Induced Phase Transformations and Their Implications on Pharmaceutical Product Quality	329
	<i>Seema Thakral, Ramprakash Govindarajan, and Raj Suryanarayanan</i>	
12.1	Introduction	329
12.2	Pharmaceutical Processes Causing Unintended Phase Transformations	333

12.2.1	Milling	333
12.2.2	Granulation and Drying – Hydration and Dehydration	336
12.2.2.1	Hydrate Formation	337
12.2.2.2	Dehydration	338
12.2.3	Compression	342
12.2.4	Freezing Aqueous Solutions	345
12.3	Pharmaceutical Processes Causing Intended Phase Transformations – Obtaining the Desired Physical Form	346
12.3.1	Spray-drying	346
12.3.2	Freeze-drying	347
12.3.3	Hot Melt Extrusion	349
12.3.4	Co-milling/Co-grinding	350
12.4	Phase Transformations During Pharmaceutical Processing – Implications	351
12.4.1	Creating Disorder – Amorphization	352
12.4.1.1	Altered Particulate and Bulk Properties	352
12.4.1.2	Implications on Chemical Stability	353
12.4.1.3	Solubility and Bioavailability Enhancement	356
12.4.2	Formation of Crystalline Mesophases	357
12.4.3	Restoring Order – Promoting In-process Recrystallization	358
12.4.3.1	In Frozen Solutions	358
12.4.3.2	Miscellaneous Processes	359
12.4.4	Amorphization and Crystallization During Freeze-drying	359
12.4.5	Changes in Chemical Composition	364
12.4.5.1	Hydrate Formation and Dehydration	364
12.4.5.2	“Co-amorphization”	365
12.4.5.3	Co-crystal Formation	366
12.4.5.4	Salt Formation and Disproportionation	366
12.5	Conclusion	368
	References	369
13	Surface and Mechanical Properties of Molecular Crystals	381
	<i>M. Teresa Carvajal and Xiang Kou</i>	
13.1	Introduction	381
13.2	Surface Properties	382
13.2.1	Structure–Property–Response/Performance	385
13.2.2	Case Study #1 – Milling-Induced Agglomeration	386
13.2.3	Case Study #2 – Batch-to-batch Variability	390
13.2.4	Case Study #3 – Hydration–Dehydration	393
13.2.5	Case Study #4 – Surface Interactions and Bulk Properties	395
13.3	Remarks	399
13.4	Impact of Polymorphism on Powder Flow	401
13.5	Impact of Polymorphism on Mechanical Properties of Molecular Crystals	402
13.6	Impact of Polymorphism on Size Reduction by Milling	405
13.7	Impact of Polymorphism on Powder Compaction Properties	406
	References	409

14	Analytical Tools to Characterize Solid Forms	415
	<i>Rolf Hilfiker, Susan M. De Paul, and Timo Rager</i>	
14.1	Crystal Structure	415
14.1.1	X-ray Diffraction (XRD)	416
14.1.2	Vibrational Spectroscopy (Raman, mid-IR, NIR, and THz)	417
14.1.3	Solid-State NMR (ssNMR) Spectroscopy	424
14.2	Thermodynamic Properties	431
14.2.1	Differential Scanning Calorimetry (DSC)	431
14.2.2	Isothermal Microcalorimetry (IMC)	436
14.2.3	Solution Calorimetry (SolCal)	438
14.3	Composition Solvate/Hydrate Stoichiometry	439
14.3.1	Thermogravimetry (TGA, TG-FTIR, and TG-MS)	439
14.3.2	Dynamic Vapor Sorption (DVS)	440
14.4	Conclusion	443
	References	443
15	Industry Case Studies	447
	<i>Ralph Diodone, Pirmin C. Hidber, Michael Kammerer, Roland Meier, Urs Schwitter, and Jürgen Thun</i>	
15.1	Introduction	447
15.1.1	Screening and Selection of Solid Forms	447
15.1.2	Control Strategy for the Solid Form	448
15.2	Case Study #1: Holistic Control Strategy for Solid Form	449
15.2.1	Solid-Form Control for Drug Substance	449
15.2.2	Solid-Form Control for Drug Product	450
15.3	Case Study #2: Solid-Form Control of API for Low-Dose Drug	451
15.4	Case Study #3: Development of Crystallization Process and Unexpected Influence of Impurity	453
15.5	Case Study #4: Hydrate/Anhydrate Dilemma	456
15.6	Case Study #5: <i>Quality by Design</i> by Selecting a Cocrystal	458
15.7	Case Study #6: Dealing with the Consecutive Appearance of New Polymorphs	460
15.8	Case Study #7: Amorphous API: Issues to be Considered in Drug Development	464
15.9	Case Study #8: Computational Prediction of Unknown Polymorphs and Experimental Confirmation	466
	References	467
16	Pharmaceutical Crystal Forms and Crystal-Form Patents:	
	Novelty and Obviousness	469
	<i>Joel Bernstein and Jill MacAlpine</i>	
16.1	Introduction	469
16.2	Novelty and Obviousness	470
16.3	The Scientific Perspective	471
16.3.1	Novelty from a Scientific Perspective	471
16.3.2	Obviousness from a Scientific Perspective	472
16.4	The Role of Serendipity in Crystal Forms	475

16.5	History of Crystal-Form Patents	477
16.6	Typical <i>Ex Post Facto</i> Arguments on Obviousness	478
16.7	Conclusion	482
	Acknowledgment	482
	References	482
	Index	485